Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched in other brain neurons (50 nCPM) | 1.00 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 128 | 0.76 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11637
Sealed predictions
- SCGN in dopamine neurons, braak+0.72 (p 0.028) → +0.11 (p 0.778)receipt 11646
Swarm cases
receipt 11646: SCGN in dopamine neurons, braak
- power
- full sample +0.34 (p 0.170, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.170, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.45 (p 0.060, n 18). could be the mix.
- skeptic
- leave-one-out range +0.24 to +0.50, sign flips 0; without severely affected donors +0.34 (p 0.170, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCGN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts